AstraZeneca PLC vs Eli Lilly and Company: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and Eli Lilly and Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating Eli Lilly and Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and Eli Lilly and Company is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against $65.2B for Eli Lilly and Company, while their respective market capitalizations stand at $275.0B and $1.05T. AstraZeneca PLC is headquartered in United Kingdom and Eli Lilly and Company operates from United States, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca makes money primarily from patented prescription medicines, plus alliance and collaboration revenue. Its scale depends on clinical development, regulatory approvals, market access, lifecycle management, and global commercial execution.

Eli Lilly and Company: Lilly has transformed from a broad pharmaceutical company into one of the world's most valuable drugmakers because of its cardiometabolic portfolio and pipeline. The core question is how long demand, capacity, and patent protection can compound.

AstraZeneca PLC and Eli Lilly and Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and Eli Lilly and Company.

AstraZeneca PLC business model: The company maintains a harmonised listing on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange, and sells medicines in more than 125 countries. Collaboration Revenue, which includes milestone payments, upfront fees from partnership arrangements, and royalties on out-licensed intellectual property, added $1.1 billion in 2025. Surprisingly, the rare disease market's high barriers to entry, including complex biologics manufacturing, small patient populations, and specialized diagnostic requirements, protect AstraZeneca's pricing power but also limit the addressable market size. These targets require not merely product success but also commercial execution, pricing negotiation, and reimbursement approval across dozens of regulatory jurisdictions. Here's why: the merger also triggered regulatory scrutiny, with the U.S. Federal Trade Commission requiring the divestiture of Zeneca's rights to levobupivacaine, a long-acting local anesthetic, to preserve competition in a market where Astra was the dominant supplier.

Eli Lilly and Company business model: Eli Lilly makes money by discovering, developing, manufacturing, and selling branded prescription medicines. Revenue depends on approved therapies, patents, clinical outcomes, manufacturing capacity, payer access, and global regulatory approvals.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of Eli Lilly and Company.

AstraZeneca PLC competitive advantage: AstraZeneca's competitive position is strengthened by its integrated oncology ecosystem, rare disease complement platform, and emerging presence in weight management and cell therapy. The DAPA-HF and DAPA-CKD trials gave Farxiga a first-mover advantage in heart failure that Jardiance has since matched, but Farxiga's earlier approval and broader label have maintained its leadership position. The gross profit margin on Product Sales was 84% in 2025, reflecting higher manufacturing costs and product mix shifts, with the company targeting margin improvement through scale efficiencies and biologics mix expansion. AstraZeneca's single most defensible competitive moat is its integrated oncology ecosystem, which combines targeted small molecules, immuno-oncology biologics, antibody-drug conjugates, and radiopharmaceuticals into a portfolio that no competitor can replicate in under a decade. The company's R&D productivity metrics support this moat: AstraZeneca achieved 74 regulatory events and 24 pipeline progression events in 2024, with 16 positive Phase III readouts in 2025 and a pipeline of 186 projects including 19 new molecular entities in late-stage development. The company's geographic diversification further strengthens the moat: AstraZeneca is the number one pharmaceutical company in Emerging Markets, including China, and holds top-three positions in Europe and Japan, meaning that no single market disruption can destabilize the overall enterprise. The success of these bets depends on flawless execution across clinical development, regulatory approval, manufacturing scale-up, and commercial launch, a sequence of complex activities where any single failure could delay revenue targets by years. The spinoff gave Zeneca independence, a strong oncology portfolio, and the need to find scale it couldn't achieve alone in an industry that was consolidating globally.

Eli Lilly and Company competitive advantage: Lilly's advantage comes from high-value intellectual property, clinical-development execution, biologics manufacturing scale, commercial access, and a concentrated portfolio of medicines with large addressable markets.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and Eli Lilly and Company each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy centers on oncology expansion, rare disease from Alexion, cardiovascular and renal medicines, respiratory and immunology launches, pipeline execution, and manufacturing/R&D investment.

Eli Lilly and Company growth strategy: Lilly is investing heavily in manufacturing capacity, next-generation obesity and diabetes drugs, oncology, immunology, neuroscience, and external collaborations to extend growth beyond the first tirzepatide wave.

A closer look at the financial trajectory of AstraZeneca PLC and Eli Lilly and Company rounds out the comparison.

AstraZeneca PLC: AstraZeneca reported FY2025 total revenue of $58.739B, up 9% at actual exchange rates, and profit for the year of $10.233B. Growth was driven by oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease medicines. The strategic questions are pipeline productivity, patent exposure, China and U.S. policy risk, and execution toward the company's 2030 revenue ambitions.

Eli Lilly and Company: Lilly reported 2025 revenue of $65.179 billion and net income of $20.640 billion. Revenue rose sharply from $45.043 billion in 2024 as demand for Mounjaro and Zepbound expanded.